Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Care of older people

Medication dosing could be 'poisoning' older people because of age exclusion in clinical trials

A House of Lords inquiry has highlighted the damaging effects of excluding older people from clinical trials.

Older person taking pills

Source: Shutterstock.com

Witnesses at the House of Lords evidence session highlighted the importance of including people aged over 65 years in clinical trials

Older patients are often being ‘poisoned’ because licensed doses of drugs are only tested in younger, healthy populations, witnesses have told a House of Lords Science and Technology Committee inquiry.

Speaking at the committee’s Ageing: Science, Technology and Healthy Living inquiry on 29 October 2019, Munir Pirmohamed, professor of molecular and clinical pharmacology at the University of Liverpool, said: “If you look at the general population coming into hospital, 6.5% of all people coming into hospitals are admitted because of adverse drug reactions (ADRs), 15% develop ADRs while in hospital … at this very moment in time 8,000 beds are occupied by patients with ADRs.

“If you look at the age profile it’s mostly [older people] and those on multiple drugs that are developing the ADRs.”

Pirmohamed added that the majority of patients he now sees are on “10, 15 or 20 drugs”, but highlighted that these drugs are frequently given at “conventional doses” that have only been tested in younger populations.

“When we use a drug at a dose which is licensed, we are often poisoning [older people] because of the dosing we are using. As you get older your kidney function declines, hepatic function declines, other functions decline … and you also have drug–drug interactions.”

“[Older people] may require multiple drugs … but we need to treat them at the appropriate doses as well, which we don’t do.”

Miles Witham, professor of trials for older people at Newcastle University’s Institute of Neuroscience, highlighted the problem of polypharmacy and ADRs in the older population at the evidence session.

He said that, for a long time, there had been a perception that including older people in clinical trials was “messy” and spoiled “nice clean [clinical] trials”.

“Historically, older people were explicitly excluded from clinical trials — no one above 65 [years] … they get ill, sometimes they die — it isn’t terribly convenient,” he said.

“Explicit exclusion on the basis of age is less common now … but people are still excluded because of multimorbidity.”

Witham highlighted the importance of including people aged over 65 years in clinical trials, suggesting the introduction of incentives and making sure the right regulatory environment exists to support it.

Pirmohamed also told the committee that there needed to be a change in the current model of care for older people to a “generalist care” model involving a multidisciplinary team that includes care homes, people “who know about drugs”, and GPs working together.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20207271

Readers' comments (1)

  • People with intellectual disabilities and medical research.

    People with intellectual/learning disabilities (ID) are exposed to the same medical interventions as everyone else.
    They experience the same illnesses often at a younger age than the general population. They are often prescribed multiple medications.

    People with ID often have unique health profiles and may not react to medications and medical treatments the same as people without ID.

    One study (1) found that only 6 (2%) of 300 randomly chosen studies clearly included persons with ID. Over 90% of studies were designed in ways that would automatically exclude people with ID from participating. The findings of this study highlight the exclusion of people with ID in medical research.

    This fact may not be widely known.

    https://www.ncbi.nlm.nih.gov/pubmed/24001184
    J Intellect Disabil Res. 2014 Sep;58(9):800-9. doi: 10.1111/jir.12091. Epub 2013 Sep 3.
    Where are persons with intellectual disabilities in medical research? A survey of published clinical trials.
    Feldman MA(1), Bosett J, Collet C, Burnham-Riosa P.

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • MCQs in Clinical Pharmacy

    MCQs in Clinical Pharmacy

    Four practice tests, each with 80 practice-oriented MCQs. Assess your knowledge of clinical issues, evaluative and analytical skills.

    £25.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Pathology and Therapeutics for Pharmacists

    Pathology and Therapeutics for Pharmacists

    An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.

    £54.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.